Morristown, NJ – According to filings with the U.S. Securities and Exchange Commission, Neumentum is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Scott Shively played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neumentum
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with 6 novel non-opioid products in development to treat pain, both in the U.S. and around the world. The Company aims to address shortfalls of current pain management treatments by developing and commercializing effective and safe, non-opioid options without the risks of abuse, misuse, and diversion seen with opioids, or the opioid-induced side effects, including potentially life-threatening respiratory depression. Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to moderately severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization.

To learn more about Neumentum, visit http://neumentum.com/

Contact:
Scott Shively, Chief Executive Officer
833-638-7246
scottshively@neumentum.com
https://www.linkedin.com/in/r-scott-shively/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved